Method and probe set for detecting cancer
Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
1. A method of detecting bladder cancer comprising:
(a) obtaining a kit comprising a set of detectably labeled chromosomal probes consisting of centromeric probes to chromosomes 3, 7, and 17 or centromeric chromosomal probes to chromosomes 3, 7, 17 and a locus-specific probe to 9p21, wherein the probes are fluorescently labeled such that each probe can be distinctly visualized in a hybridization pattern;
(b) hybridizing said set of chromosomal probes of said kit to cells obtained from a urine sample from a subject; and
(c) detecting bladder cancer by identifying aneusomic cells from the hybridization pattern of said set of chromosomal probes in cells from said urine sample.
2. The method of claim 1 , comprising selecting a plurality of cytologically abnormal cells from said urine sample and detecting aneusomic cells in said selected cells by examining the hybridization pattern of said set of chromosomal probes in each of said selected cells.
3. The method of claim 1 , wherein said probes are fluorescently labeled with a combination of fluorophores selected from the group consisting of 7-amino-4-methylcoumarin-3-acetic acid (AMCA), 5-carboxy-X-rhodamine, 6-carboxy-X-rhodamine, lissamine rhodamine B, 5-carboxyfluorescein, 6-carboxyfluorescein, fluorescein-5-isothiocyanate (FITC), 7-diethylaminocoumarin-3-carboxylic acid, tetramethylrhodamine-5-isothiocyanate, tetramethylrhodamine-6-isothiocyanate, 5-carboxytetramethylrhodamine, 6-carboxytetramethylrhodamine, 7-hydroxycoumarin-3-carboxylic acid, 6-[fluorescein 5-carboxamido]hexanoic acid, 6-[fluorescein 6-carboxamido]hexanoic acid, N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a diaza-3-indacenepropionic acid, eosin-5-isothiocyanate, and erythrosin-5-isothiocyanate.
4. The method of claim 2 , wherein cells are selected by nuclear morphology.
5. The method of claim 2 , wherein cells are selected by nuclear size.
6. The method of claim 2 , wherein cells are selected by shape of nucleus.
7. The method of claim 4 , wherein nuclear morphology is assessed by DAPI staining.